Table 1

Clinical characteristics and amplification data of primary tumour samples and cell lines

Sample No		Code		Dx		Gender		Age (y)		Outcome		CGH		Enhanced RLGS fragments
Sample No		Code		Dx		Gender		Age (y)		Outcome		CGH		4C20 (2)	4C23 (2)	4F62 (2)	3D45 (ND)	3C2 (ND)	3F6 (ND)	3G68 (ND)	3C15 (ND)	3C36 (ND)	5C10 (ND)	5B35 (ND)	4C3 (8)	3B35 (8)	4A5 (2)	4A23 (2)	3C25 (2)	4F53 (2)	3G75 (ND)	5E60 (ND)
1	0107	MB	M	26	D
2	1014	MB	F	2	A							+
3	9704P191	MB	M	7	A
4	9707P304	MB	M	3	D
5	9609P256	MB	M	6	D	+2p24, +3p25, +7q32-	+	+	+
						35, −9q, +10p, −10q23-ter, +12p13, +13q32, −15q26, +18, +19p13.3, −19q13.3-ter, −20p13, +21, −Xq26-ter
6	9601P300	MB	M	4	A	-4q26-ter, +7q11.21,−8p23, +8q23-ter, −9p, −16q							+		+	+	+
						-4q26-ter, +7q11.21,−8p23, +8q23-ter, −9p, −16q
7	9501P002	MB	M	7	A							+					+
8	9503P010	MB	M	9	A	+4q16, +5p15, −9q				+	+	+	+
9	9712P611	MB	F	12	A
10	9410P009	MB	M	16	A							+
11	9001Z04	MB	M	6	A
12	9812P5013	MB	M	14	A												+
13	9501P050	MB	M	6	A
14	9611P246	MB	F	5	A
15	9709P601	MB	M	6	A
16	9708P618	MB	F	14	A
17	9903P901	MB	M	6	A		+					+		+
18	9001EE01	MB	M	6	A
19	9905P6002	MB	M	6	A
20	203	MB	F	4	A								+
21	9805P620	PN^1-150	F	7	D		+		+									+		+	+	+	+	+	+
22	9501P003	PN	M	3	D
23	9602P366	PN	M	4	A
24	9408P004	PN	F	3	D
25	8910Z01	PN	M	6	?							+
26	D341-MED																	+	+
27	D283-MED																		+
28	Daoy
29	MMH-MED-1
30	MMH-PNET-5

Dx, diagnosis; MB, medulloblastoma; PN, supratentorial PNET, A, alive; D, dead; ?, lost to follow up; + enhanced RLGS fragment.
↵1-150 Secondary tumour 2 years after chemotherapy and radiation for a primary medulloblastoma.
The chromosomal location ((2), (8), or (ND), chromosome 2, 8, or assignment not possible) of RLGS fragments was determined using the CA-RLGS profile.22